Top Page
Medley
(4480)
Medley (4480) vs. iShares MSCI Japan ETF (EWJ)
Medley Business Overview & Revenue Model
Medley Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.06B | 36.79B | 29.30B | 20.53B | 14.19B | 10.86B |
| Gross Profit | 20.74B | 23.19B | 18.92B | 13.59B | 9.72B | 6.99B |
| EBITDA | 5.03B | 4.61B | 4.00B | 4.50B | 2.14B | 1.25B |
| Net Income | 1.44B | 975.00M | 2.80B | 2.57B | 1.02B | 563.00M |
Balance Sheet | ||||||
| Total Assets | 47.42B | 41.25B | 45.20B | 25.43B | 21.81B | 20.21B |
| Cash, Cash Equivalents and Short-Term Investments | 13.52B | 8.57B | 19.00B | 15.35B | 14.42B | 14.29B |
| Total Debt | 18.27B | 16.09B | 15.18B | 1.66B | 2.38B | 3.11B |
| Total Liabilities | 29.36B | 26.45B | 24.98B | 7.79B | 6.64B | 6.16B |
| Stockholders Equity | 18.07B | 14.80B | 20.21B | 17.55B | 15.08B | 13.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.28B | 2.38B | 3.47B | 1.64B | 796.39M |
| Operating Cash Flow | 0.00 | 3.49B | 2.45B | 3.87B | 2.01B | 1.04B |
| Investing Cash Flow | 0.00 | -7.13B | -10.72B | -1.66B | -751.00M | -3.29B |
| Financing Cash Flow | 0.00 | -6.78B | 11.90B | -1.22B | -927.00M | 2.22B |
Medley Technical Analysis
Medley Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥1.17T | 23.50 | 12.15% | 1.01% | 33.50% | 17.26% | |
70 Outperform | ¥11.22B | 29.02 | ― | 5.30% | 0.09% | -48.79% | |
63 Neutral | ¥65.48B | 226.81 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥273.19B | 39.51 | ― | 0.43% | 20.55% | 48.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥64.95B | 64.70 | 8.79% | ― | 31.95% | -40.95% | |
45 Neutral | ¥3.02B | -5.60 | ― | ― | 16.19% | -4.42% |
Medley Corporate Events
Medley has proposed reappointing its existing board, including President and CEO Kohei Takiguchi and CFO Ryo Kawahara, with all internal and independent external directors slated for re-nomination at the upcoming shareholders’ meeting in March 2026. The company also set its executive and management structure for the fiscal year ending December 2026, clarifying leadership roles across its HR and medical platform businesses, finance, legal and compliance, and corporate functions, signaling continuity in governance and a stable organizational framework as it executes its business strategy.
The new structure will see Takiguchi continue as representative director and CEO, with Ishizaki leading the HR Platform Business and Shishido and Yamazaki heading technology for the Medical Platform Business. Medley is reinforcing specialized roles such as CHRO, GC, VPoE, and CFO positions within both HR and medical platforms, which is likely aimed at strengthening operational oversight, technological development, and corporate governance to support long-term growth and stakeholder confidence.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
Medley reported consolidated net sales of ¥36.79 billion for the fiscal year ended Dec. 31, 2025, up 25.5% year on year, while EBITDA rose 17.2%, but operating profit fell 7.6% and profit attributable to owners of parent dropped 65.1% amid a sharp decline in ordinary profit. Total assets shrank to ¥41.25 billion and the equity ratio slid to 35.9%, reflecting heavier cash outflows from investing and financing activities, though the company ended the year with ¥8.58 billion in cash and cash equivalents and again paid no dividends.
The company expects a rebound in profitability in 2026, forecasting a 26.1% rise in net sales to ¥46.4 billion and an 84.5% jump in profit attributable to owners of parent to ¥1.8 billion, with a stronger operating margin. Medley also streamlined its consolidation scope by deconsolidating three subsidiaries, a move that could sharpen its strategic focus, while maintaining a zero‑dividend policy to prioritize reinvestment and balance sheet management.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
Medley, Inc., listed on the Tokyo Stock Exchange Prime Market, has an authorized share repurchase program for its common stock, allowing buybacks of up to 1.5 million shares, or 4.8% of its outstanding shares excluding treasury stock, for a total of up to ¥3 billion between November 17, 2025 and March 31, 2026. This program is part of the company’s broader capital management strategy aimed at enhancing shareholder value through market purchases of its own shares.
In its latest progress update, Medley reported that it did not repurchase any shares during the period from January 1 to January 31, 2026, leaving both the number of shares bought and the amount spent at zero for that month, while cumulative repurchases under the current authorization totaled 529,100 shares for approximately ¥1.29 billion as of January 31, 2026. The pause in buybacks during January suggests a tactical approach to timing and market conditions, while the substantial amount already deployed indicates an ongoing commitment to returning capital to shareholders within the authorized timeframe.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
Medley, Inc. has resolved at its board meeting to secure a total of ¥5 billion in new financing through unsecured loans from Mizuho Bank and Sumitomo Mitsui Banking Corporation, with a five-year term and equal principal repayment structure. The funds will be used for long-term working capital and the acquisition of treasury shares, a move that may support capital efficiency and shareholder value, while the company expects no significant impact on its current fiscal year consolidated results but has committed to further disclosure if the outlook changes materially.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
Medley, Inc. reported progress on its ongoing share repurchase program, disclosing that it bought back 234,500 common shares for a total of 566.9 million yen via market transactions on the Tokyo Stock Exchange between December 1 and December 31, 2025. Under the broader repurchase authorization approved by the board in November 2025—allowing buybacks of up to 1.5 million shares or 3.0 billion yen through March 31, 2026—the company has, as of December 31, 2025, cumulatively repurchased 529,100 shares for approximately 1.29 billion yen, signaling continued execution of its capital allocation policy and a focus on enhancing shareholder value through reducing shares outstanding.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
Medley, Inc. has announced the progress of its share repurchase program, which was resolved at a board meeting on November 14, 2025. The company repurchased 294,600 common shares for a total of 723,474,500 yen through market transactions on the Tokyo Stock Exchange between November 17 and November 30, 2025. This initiative is part of a larger plan to repurchase up to 1.5 million shares, amounting to 3,000 million yen, by March 31, 2026.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.